Table 3.
OR (95% CI)b | P valueb | |
---|---|---|
Sociodemographic correlates | ||
Age (continuous variable) | 1.06 (0.97–1.17) | .186 |
Education level | ||
Primary school not completedc | 1.23 (0.26–5.90) | .795 |
Primary school completedc | 1.80 (0.31–10.5) | .514 |
Secondary school not completedc | 0.33 (0.02–4.74) | .417 |
Exchanged sex for money/goods in month prior to posttreatment visit | 5.40 (0.56–52.08) | .145 |
Used a condom at the last vaginal sex act prior to posttreatment visit | 0.99 (0.97–1.02) | .678 |
Condom use in the 2 weeks prior to posttreatment visit | ||
Always vs never | 0.36 (0.03–3.92) | .399 |
Sometimes (but not always) vs never | 0.22 (0.02–2.19) | .196 |
Currently using hormonal contraception at the posttreatment visit | 0.69 (0.23–2.05) | .499 |
Currently breastfeeding at the posttreatment visit | 1.00 (0.97–1.03) | .874 |
Inserted anything in vagina in the 12 months prior to posttreatment visit | 1.03 (0.34–3.10) | .959 |
Had menses in 7 days prior to posttreatment visit | 1.83 (0.41–8.23) | .429 |
Reported any urogenital symptoms at the pretreatment visit | 0.67 (0.21–2.11) | .496 |
Reported any urogenital symptoms at the posttreatment visit | NAd | NAd |
Biological correlates (at pretreatment visit) | ||
Total lactobacilli concentration | 1.14 (0.80–1.62) | .476 |
Total BV-anaerobes concentration | 0.79 (0.41–1.53) | .489 |
Total pathobionts concentration | 0.76 (0.58–0.99) | .044 |
Total other bacteria concentration | 0.83 (0.63–1.10) | .191 |
Gardnerella vaginalis concentratione | 0.86 (0.44–1.65) | .640 |
Atopobium vaginae concentrationf | 0.83 (0.59–1.17) | .285 |
Prevotella concentration | 0.93 (0.65–1.33) | .691 |
Sneathia concentration | 0.86 (0.63–1.16) | .318 |
Megasphaera concentration | 1.12 (0.89–1.42) | .333 |
Veillonella concentration | 0.85 (0.68–1.06) | .157 |
BVAB1 concentration | 1.01 (0.83–1.23) | .912 |
Fusobacterium concentration | 0.89 (0.61–1.30) | .549 |
Vaginal microbiota type | ||
LA vs Li | 1.75 (0.10–30.84) | .702 |
BV_GV vs Li | 0.46 (0.04–5.75) | .550 |
BV_noGV vs Li | 0.67 (0.04–11.29) | .779 |
GV vs Li | 0.30 (0.02–4.91) | .398 |
BV_GV vs LA | 0.27 (0.05–1.52) | .136 |
BV_noGV vs LA | 0.38 (0.04–3.34) | .383 |
GV vs LA | 0.17 (0.02–1.44) | .104 |
Pooled vaginal microbiota type | ||
LA vs Lactobacillus-dominated [Li or Lo] | 1.75 (0.10–30.84) | 0.702 |
[BV_GV or BV_noGV or GV] vs Lactobacillus-dominated [Li or Lo] | 0.45 (0.04–5.40) | 0.532 |
Yeasts on wet mount | 0.83 (0.05–13.9) | 0.896 |
Trichomonas vaginalis on wet mount | 1.71 (0.15–20.1) | 0.661 |
Positive urinalysis test | 1.22 (0.33–4.44) | 0.765 |
Any bacterial sexually transmitted infection (CT/NG/syphilis) | 0.65 (0.22–1.91) | 0.435 |
Positive herpes simplex virus type 2 serology | 2.16 (0.70–6.69) | 0.178 |
BV, bacterial vaginosis; BVAB1, BV-associated bacterium type 1; BV_GV, polybacterial Gardnerella vaginalis-containing; BV_noGV, polybacterial but low G. vaginalis; CI, confidence interval; CT, Chlamydia trachomatis; GV, G. vaginalis-dominated; LA, lactobacilli and anaerobes; Li, L. iners-dominated; Lo, other lactobacilli-dominated; NA, not applicable; NG, Neisseria gonorrhoeae; OR, odds ratio.
Verwijs et al. Impact of oral metronidazole treatment on the vaginal microbiota and correlates of treatment failure. Am J Obstet Gynecol 2020.
Successful treatment defined as Nugent 7–10 pre- and 0–3 posttreatment (n=30 women) and treatment failure as Nugent 7–10 pre and 4–10 posttreatment (n=25 women)
Bivariable logistic regression models
Compared with no schooling
No women reported urogenital symptoms at the posttreatment visit
Includes reads assigned to Gardnerella genus
Includes reads assigned to Atopobium genus.